Phase 1 study in patients with metastatic melanoma of immunization with dendritic cells presenting epitopes derived from the melanoma-associated antigens MART-1 and gp100 - PubMed (original) (raw)
Clinical Trial
Phase 1 study in patients with metastatic melanoma of immunization with dendritic cells presenting epitopes derived from the melanoma-associated antigens MART-1 and gp100
M C Panelli et al. J Immunother. 2000 Jul-Aug.
Abstract
Dendritic cells (DCs) have been shown to enhance anti-tumor immune responses in several preclinical models. Furthermore, DC-like function can be elicited from peripheral blood monocytes cultured in vitro with interleukin-4 and granulocyte-macrophage colony-stimulating factor. For this reason, a phase 1 study was initiated at the Surgery Branch of the National Cancer Institute to test the toxicity and biological activity of the intravenous administration of peripheral blood monocyte-derived DCs. The DCs were generated by 5- to 7-day incubation in interleukin-4 (1,000 U/mL) and granulocyte-macrophage colony-stimulating factor (1,000 U/mL) of peripheral blood monocytes obtained by leukapheresis. Before administration, the DCs were pulsed separately with the HLA-A*0201-associated melanoma epitopes MART-1(27-35) and gp-100-209-2M. The DCs were administered four times at 3-week intervals. A first cohort of patients (n = 3) was treated with 6 x 10(7) DCs and a second cohort (n = 5) with 2 x 10(8) DCs (in either case, one half of the DCs were pulsed with MART-1(27-35) and the other half was pulsed with gp-100-209-2M). In a final cohort under accrual (n = 2) 2 x 10(8) DCs were administered in combination with interleukin-2 (720,000 IU/kg every 8 hours). The recovery of DCs after in vitro culture ranged from 3% to 35% (mean, 15%) of the original peripheral blood monocytes. Administration of DCs caused no symptoms at any of the doses, and the concomitant administration of interleukin-2 did not cause toxicity other than that expected for interleukin-2 alone. Monitoring of patients' cytotoxic T lymphocyte reactivity before and after treatment revealed enhancement of cytotoxic T lymphocyte reactivity only in one of five patients tested. Of seven patients evaluated for response, one had a transient partial response with regression of pulmonary and cutaneous metastases. A relatively large number of DCs can be safely administered intravenously. The poor clinical outcome of this study perhaps could be explained by the type of protocol used for DC maturation, the route of administration, or both. For this reason, this clinical protocol was interrupted prematurely, whereas other strategies for DC preparation and route of administration are being investigated at the authors' institution.
Similar articles
- Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
Palucka AK, Ueno H, Connolly J, Kerneis-Norvell F, Blanck JP, Johnston DA, Fay J, Banchereau J. Palucka AK, et al. J Immunother. 2006 Sep-Oct;29(5):545-57. doi: 10.1097/01.cji.0000211309.90621.8b. J Immunother. 2006. PMID: 16971810 Clinical Trial. - Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients.
de Vries IJ, Lesterhuis WJ, Scharenborg NM, Engelen LP, Ruiter DJ, Gerritsen MJ, Croockewit S, Britten CM, Torensma R, Adema GJ, Figdor CG, Punt CJ. de Vries IJ, et al. Clin Cancer Res. 2003 Nov 1;9(14):5091-100. Clin Cancer Res. 2003. PMID: 14613986 - Novel approach to the characterization of melanoma associated-peptide-specific CTL lines from Japanese metastatic melanoma patients.
Akiyama Y, Maruyama K, Tai S, Takikawa M, Ohshita C, Yamamoto A, Yamazaki N, Kiyohara Y, Yamaguchi K. Akiyama Y, et al. Int J Oncol. 2008 Sep;33(3):433-41. Int J Oncol. 2008. PMID: 18695871 - Dendritic cell gene therapy.
Onaitis M, Kalady MF, Pruitt S, Tyler DS. Onaitis M, et al. Surg Oncol Clin N Am. 2002 Jul;11(3):645-60. doi: 10.1016/s1055-3207(02)00027-3. Surg Oncol Clin N Am. 2002. PMID: 12487060 Review. - Novel dendritic cell-based vaccination in late stage melanoma.
Schneble EJ, Yu X, Wagner TE, Peoples GE. Schneble EJ, et al. Hum Vaccin Immunother. 2014;10(11):3132-8. doi: 10.4161/hv.29110. Hum Vaccin Immunother. 2014. PMID: 25483650 Free PMC article. Review.
Cited by
- Multi-antigen spherical nucleic acid cancer vaccines.
Teplensky MH, Evangelopoulos M, Dittmar JW, Forsyth CM, Sinegra AJ, Wang S, Mirkin CA. Teplensky MH, et al. Nat Biomed Eng. 2023 Jul;7(7):911-927. doi: 10.1038/s41551-022-01000-2. Epub 2023 Jan 30. Nat Biomed Eng. 2023. PMID: 36717738 Free PMC article. - Cancer stem cells, plasticity, and drug resistance.
Lionetti MC, Fumagalli MR, La Porta CAM. Lionetti MC, et al. Cancer Drug Resist. 2020 Feb 21;3(2):140-148. doi: 10.20517/cdr.2019.112. eCollection 2020. Cancer Drug Resist. 2020. PMID: 35582613 Free PMC article. Review. - Melanoma therapeutics: a literature review.
Dhanyamraju PK, Patel TN. Dhanyamraju PK, et al. J Biomed Res. 2022 Feb 28;36(2):77-97. doi: 10.7555/JBR.36.20210163. J Biomed Res. 2022. PMID: 35260531 Free PMC article. - Vaccines as Priming Tools for T Cell Therapy for Epithelial Cancers.
Kandalaft LE, Harari A. Kandalaft LE, et al. Cancers (Basel). 2021 Nov 19;13(22):5819. doi: 10.3390/cancers13225819. Cancers (Basel). 2021. PMID: 34830973 Free PMC article. Review. - Nanoparticle-based approaches to target the lymphatic system for antitumor treatment.
Peng X, Wang J, Zhou F, Liu Q, Zhang Z. Peng X, et al. Cell Mol Life Sci. 2021 Jun;78(12):5139-5161. doi: 10.1007/s00018-021-03842-6. Epub 2021 May 8. Cell Mol Life Sci. 2021. PMID: 33963442 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials